Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Research output: Contribution to journalDebate/Note/Editorial

Details

Authors
  • Nam H. Dang
  • Michinori Ogura
  • Sylvie Castaigne
  • Luis E. Fayad
  • Mats Jerkeman
  • John Radford
  • Antonio Pezzutto
  • Igor N. Bondarenko
  • Douglas A. Stewart
  • Michael Shnaidman
  • Sharon Sullivan
  • Erik Vandendries
  • Kensei Tobinai
  • Radhakrishnan Ramchandren
  • Paul A. Hamlin
  • Eva Giné
  • Kiyoshi Ando
Organisations
External organisations
  • University of Florida
  • Tokai Central Hospital
  • Versailles Saint-Quentin-en-Yvelines University
  • University of Texas
  • University of Manchester
  • Charité Universitätsmedizin Berlin
  • Academy of Medical Sciences of Ukraine
  • University of Calgary
  • Pfizer Inc. US
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology

Keywords

  • Antibody-drug conjugate, B-cell non-Hodgkin lymphoma, CD22+, Inotuzumab ozogamicin, Rituximab
Original languageEnglish
Pages (from-to)583-586
JournalBritish Journal of Haematology
Volume182
Issue number4
Early online date2017
Publication statusPublished - 2018
Publication categoryResearch
Peer-reviewedYes